SAN DIEGO, Feb. 8, 2018 /PRNewswire/
-- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine
technology innovation, focused on transforming spine surgery with
minimally disruptive, procedurally-integrated solutions, announced
the appointment of John A. DeFord,
Ph.D. to the Company's Board of Directors, effective upon the
filing of the Company's Form 10-K with the Securities and Exchange
Commission.
Dr. DeFord has more than 25 years of experience in the medical
device industry, with particular expertise overseeing clinical
advancement through innovative R&D and technology-based
initiatives. He currently serves as Senior Vice President, Research
and Development, Interventional Segment for BD (Becton, Dickinson
and Company). He joined BD following its December 2017 acquisition of C.R. Bard, Inc.,
where he had served as Senior Vice President, Science, Technology
and Clinical Affairs since 2007. In that role, Dr. DeFord was
responsible for R&D and clinical affairs functions across five
global corporate divisions.
"We are pleased to welcome John to the NuVasive Board," said
Gregory T. Lucier, chairman and
chief executive officer of NuVasive, Inc. "We expect John's
experience driving innovative products and technology programs at
other large medical device companies will help inform our own
strategic direction as we quicken the tempo of our product launches
and expand our efforts toward software development and a focus on
systematizing spine surgery."
"I am thrilled to have the opportunity to support NuVasive's
leadership in spine," said Dr. DeFord. "I have long admired
NuVasive as an industry innovator and look forward to sharing my
clinical and business perspectives as a member of the Board to help
the Company deliver even greater value to its surgeon customers,
patients and shareholders."
As a result of Dr. DeFord's appointment, the NuVasive Board of
Directors consists of 10 directors, nine of whom are independent.
Dr. DeFord will stand for reelection at the Company's annual
meeting where Mr. Lesley Howe and
Dr. Peter Farrell will retire from
the NuVasive Board when their current terms expire, pursuant to the
Company's director retirement age policy.
Prior to his 13-year tenure at C.R. Bard, Dr. DeFord held
various executive positions including president and chief executive
officer with Cook Incorporated, now a multi-billion dollar
privately-held medical device manufacturer, and served as managing
director at Early Stage Partners LP, a venture capital firm focused
on advanced materials, medical/biotechnology and information
technology companies.
Published in numerous scientific journals, Dr. DeFord is
currently a member of the executive faculty at Purdue University's Krannert School of Management
and Weldon School of Biomedical
Engineering. Dr. DeFord earned a B.S. and M.S. in electrical
engineering and a Ph.D. in electrical/biomedical engineering from
Purdue University. He holds numerous
patents and multiple industry honors.
About NuVasive
NuVasive, Inc. (NASDAQ:
NUVA) is the leader in spine technology innovation, focused on
transforming spine surgery and beyond with minimally disruptive,
procedurally-integrated solutions designed to deliver reproducible
and clinically-proven surgical outcomes. The Company's portfolio
includes access instruments, implantable hardware, biologics,
software systems for surgical planning, navigation and imaging
solutions, magnetically adjustable implant systems for spine and
orthopedics, and intraoperative monitoring service offerings. With
$962 million in revenues (2016),
NuVasive has an approximate 2,300 person workforce in more than 40
countries serving surgeons, hospitals and patients. For more
information, please visit www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions
you that statements included in this news release that are not a
description of historical facts are forward-looking statements that
involve risks, uncertainties, assumptions and other factors which,
if they do not materialize or prove correct, could cause NuVasive's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. The
potential risks and uncertainties which contribute to the uncertain
nature of these statements include, among others, risks associated
with acceptance of the Company's surgical products and procedures
by spine surgeons, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products (including the
iGA™ platform), the Company's ability to effectually manage
inventory as it continues to release new products, its ability to
recruit and retain management and key personnel, and the other
risks and uncertainties described in NuVasive's news releases and
periodic filings with the Securities and Exchange Commission.
NuVasive's public filings with the Securities and Exchange
Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect
events or circumstances arising after the date on which it was
made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/john-deford-to-join-nuvasive-board-of-directors-300596130.html
SOURCE NuVasive, Inc.